1.Lynn, RB, Friedman, LS. Irritable bowel syndrome. N Engl J Med. 1993;329:1940–1945.
2.Drossman, DA, McKee, DC, Sandler, RS, et al.Psychosocial factors in the irritable bowel syndrome: A multivariate analysis of patients and nonpatients with irritable bowel syndrome. Gastroenterology. 1988;95:701–708.
3.Thompson, WG. C. Functional bowel disorders and D. Functional abdominal pain. In: Drossman, DA, Richter, JE, Talley, NJ, Thompson, WG, Corazziari, E, eds. Functional Gastroinstestinal Disorders: Diagnosis, Pathophysiology and Treatment McLean, VA: Degnon and Associates; 1994:115–173.
4.Talley, NJ, Zinsmeister, AR, Van Dyke, C, Melton, LJ 3rd. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology. 1991;101:927–934.
5.Latimer, PR. Irritable bowel syndrome. Psychosomatics. 1983;24:205–218.
6.Sandler, RS, Drossman, DA, Nathan, HP, McKee, DC. Symptom complaints and health care seeking behavior in subjects with bowel dysfunction. Gastroenterology. 1984;87:314–318.
7.Whitehead, WE, Bosmajian, L, Zonderman, AB, Costa, PT Jr, Schuster, MM. Symptoms of psychologic distress associated with irritable bowel syndrome. Comparison of community and medical clinic samples. Gastroenterology. 1988;95:709–714.
8.Kaplan, HI, Freedman, AM, Sadock, BJ. Schizophrenic disorders. In: Comprehensive Textbook of Psychiatry. 3rd ed. Baltimore, Md: Lippincott Williams and Wilkins; 1980:1093–1287.
9.Gupta, S, Masand, P, Kaplan, D, Bhandary, A, Hendricks, S. The relationship between schizophrenia and irritable bowel syndrome (IBS). Schizophr Res. 1997;23:265–268.
10.Masand, P, Kaplan, D, Gupta, S, Bhandary, A, Nasra, G, Margo, K, Kline, M. Major depression and Irritable bowel syndrome (IBS): is there a relationship? J Clin Psychiatry. 1995;56:363–367.
11.Tollefson, GD, Tollefson, SL, Pederson, M, Luxenberg, M, Dunsmore, G. Comorbid irritable bowel syndrome in patients with generalized anxiety and major depression. Ann Clin Psychiatry. 1991;3:215–222.
12.Lydiard, RB. Anxiety and the irritable bowel syndrome. Psychiatric Ann. 1992;22:612–618.
13.Kaplan, D, Masand, P, Gupta, S. The relationship of irritable bowel syndrome (IBS) and panic disorder. Ann Clin Psychiatry. 1996;8:81–88.
14.Noyes, R, Cook, B, Garvey, M, Summers, R. Reduction of gastrointestinal symptoms following treatment for panic disorder. Psychosomatics. 1990;31:75–79.
15.Masand, PS, Kaplan, DS, Gupta, S. Irritable bowel syndrome and dysthymia: Is there a relationship? Psychosomatics. 1997;38:63–69.
16.Masand, PS, Kaplan, D, Gupta, S, Bhandary, A. Relationship between irritable bowel syndrome (IBS) and double depression (dysthymia plus major depression). Depression. 1996;3:303–306.
17.Gonzalez-Heydrich, J, Peroutka, SJ. Serotonin receptor and re-uptake sites: pharmacologic significance. J Clin Psychiatry. 1990;51(suppl):5–12.
18.Read, NW, Gwee, KA. The importance of 5-hydroxytryptamine receptors in the gut. Pharmacol Ther. 1994;62:159–173.
19.Longstreth, GF, Drossman, DA. New developments in the diagnosis and treatment of irritable bowel syndrome. Curr Gastroenterol Rep. 2002;4:427–434.
20.Kilkens, TOC, Honig, A, Rozendaal, N, Van Nieuwenhoven, MA, Brummer, RJM. Systematic review: serotonergic modulators in the treatment of irritable syndrome-influence on psychiatric and gastrointestinal symptoms. Aliment Pharmacol Ther. 2003;17:43–51.
21.Masand, PS, Gupta, S, Schwartz, TL, et al.Paroxetine in patients with irritable bowel syndrome (IBS): a pilot open-label study. Prim Care Companion J Clin Psychiatry. 2002;4:12–16.
22.Masand, PS, Gupta, S, Schwartz, TL, et al.Does a preexisting anxiety disorder predict response to Paroxetine in irritable bowel syndrome (IBS)? Psychosomatics. 2002;43:6:451–455.
23.Ohta, M, Suzuki, T, Ohmori, J, et al.Novel 5-hydroxytryptamine (5-HT3) receptor antagonists. III. Pharmacological evaluations and molecular modeling studies of optically active 4,5,6,7-tetrahydro-1H-benzimidazole derivatives. Chem Pharmacol Bull. 1996;44:1000–1008.
24.Sato, Y, Yamada, M, Yoshida, S, et al.Benzoxazole derivatives as novel 5-HT3 receptor partial agonists in the gut. J Med Chem. 1998;41:3015–3021.
25.Montgomery, SA. Psychopharmacology of obsessive-compulsive disorder. CNS Spectr. 1998;3(suppl 1):33–37.
26.Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
27.Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. rev. Washington, DC: American Psychiatric Association; 1987.
28.Vidyaranya, VM, Khanna, S, Virk, S, et al. Relationship of irritable bowel syndrome and obsessive compulsive disorder in India. Paper presented at: Annual Meeting of American Psychiatric Association; May 13-18, 2000; Chicago, III.
29.De Ponti, F, Malagelada, JR. Functional gut disorders: the motility to sensitivity disorders. A review of current and investigational drugs for their management. Pharmacol Ther. 1998;80:49–88.
30.Crowell, MD. The role of serotonin in the pathophysiology of irritable bowel syndrome. Am J Manag Care. 2001;7(8 suppl):S252–S260.
31.Lacy, BE, Yu, S. Tegaserod: a new 5HT4 agonist. J Clin Gastroenterol. 2002;34:27–33.
32.Schuster, NM. Diagnostic evaluation of the irritable bowel syndrome. Gastoenterol Clin N Am. 1991;20:269–278.